<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974336</url>
  </required_header>
  <id_info>
    <org_study_id>UDCA-PNAC-SBS</org_study_id>
    <nct_id>NCT01974336</nct_id>
  </id_info>
  <brief_title>The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients</brief_title>
  <official_title>The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinling Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jinling Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of UDCA in treating the parenteral nutrition-associated cholestasis(PNAC) has
      been identified by some studies in children without short bowel syndrome(SBS).Most of the
      adults who suffering PNAC have SBS. it limits the potential function of UDCA because of the
      lack of SBS patients and malabsorption of UDCA.Therefore, we design this clinical trial in
      our center of SBS to approach the preventative and therapeutical effect of UDCA to PNAC in
      adults with short bowel syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The biochemical indicator of patients' liver function during oral UDCA or placebo</measure>
    <time_frame>2 months</time_frame>
    <description>detect the biochemical indicator of patients' liver function(Serum bilirubin, GGT Valley, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase) during oral UDCA or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the changs of composition of serum bile acid after oral UDCA or placebo</measure>
    <time_frame>2 months</time_frame>
    <description>we test the composition of serum bile acid at the beginning,2 months,4 months(the end) of the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changs of the level of fibroblast growth factor 19(FGF19) in the serum</measure>
    <time_frame>4 months</time_frame>
    <description>we test the level of FGF19 in the serum at the beginning,2 months,4months(the end) of the trail.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>UDCA+placebo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15-30mg/kg/d UDCA for 2 months + placebo for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+UDCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo for 2 months+15-30mg/kg/d UDCA for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ursodeoxycholic acid</intervention_name>
    <arm_group_label>UDCA+placebo group</arm_group_label>
    <arm_group_label>placebo+UDCA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with short bowel syndrome supported by total parenteral nutrition.

          -  Patients have intestine more than 50cm.

          -  Requirements of informed consent and assent of participant, parent or legal guardian
             as applicable

          -  Consciousness and ability to cooperate.

        Exclusion Criteria:

          -  Patients have obstruction of biliary tract, infection, autoimmune disease, cancer

          -  Patients have intestine less than 50cm

          -  A clinically significant laboratory abnormality or a history of significant cardiac,
             pulmonary, hepatic, or renal disease

          -  Female with positive pregnancy

          -  Allergy to ursodeoxycholic acid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wencheng Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>200002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2013</study_first_submitted>
  <study_first_submitted_qc>October 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinling Hospital, China</investigator_affiliation>
    <investigator_full_name>Kong Wencheng</investigator_full_name>
    <investigator_title>Senior Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

